• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days.连续7天每天一次经阴道给予[14C]达匹韦林凝胶制剂后,恒河猴和兔体内达匹韦林的浓度。
Antimicrob Agents Chemother. 2008 Mar;52(3):909-14. doi: 10.1128/AAC.00330-07. Epub 2007 Dec 17.
2
Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.达匹韦林阴道杀微生物剂凝胶在健康的HIV阴性女性中的安全性、耐受性及全身吸收情况。
AIDS. 2009 Jul 31;23(12):1531-8. doi: 10.1097/QAD.0b013e32832c413d.
3
A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.一项评估新型达匹韦林阴道膜安全性、可接受性、药代动力学和药效学的1期试验。
J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):498-505. doi: 10.1097/QAI.0000000000000897.
4
Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).达匹韦林阴道凝胶与薄膜制剂的药代动力学和药效学比较(FAME 02B)。
AIDS Res Hum Retroviruses. 2017 Apr;33(4):339-346. doi: 10.1089/AID.2016.0040. Epub 2016 Dec 13.
5
Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel.2 种地匹福林阴道杀微生物剂凝胶的药代动力学及其与基于羟乙基纤维素的通用安慰剂凝胶的安全性比较。
J Acquir Immune Defic Syndr. 2010 Oct;55(2):161-9. doi: 10.1097/QAI.0b013e3181e3293a.
6
Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women.达匹韦林阴道杀微生物剂凝胶在健康的HIV阴性女性中的药代动力学评估。
AIDS Res Hum Retroviruses. 2010 Nov;26(11):1181-90. doi: 10.1089/aid.2009.0227. Epub 2010 Sep 21.
7
The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.绵羊作为候选杀微生物剂临床前安全性和药代动力学评估的模型。
Antimicrob Agents Chemother. 2015 Jul;59(7):3761-70. doi: 10.1128/AAC.04954-14. Epub 2015 Apr 6.
8
Pharmacokinetic and Pharmacodynamic Evaluation following Vaginal Application of IQB3002, a Dual-Chamber Microbicide Gel Containing the Nonnucleoside Reverse Transcriptase Inhibitor IQP-0528 in Rhesus Macaques.含非核苷类逆转录酶抑制剂IQP-0528的双腔杀微生物凝胶IQB3002经阴道给药后在恒河猴体内的药代动力学和药效学评价
Antimicrob Agents Chemother. 2015 Dec 14;60(3):1393-400. doi: 10.1128/AAC.02201-15.
9
Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women.达匹韦林从基质型和储库型阴道环向HIV阴性女性体内递送的安全性和药代动力学
J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):416-23. doi: 10.1097/qai.0b013e3181acb536.
10
Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.含双夫定和达芦那韦的组合杀微生物剂阴道环的临床前开发。
J Antimicrob Chemother. 2014 Sep;69(9):2477-88. doi: 10.1093/jac/dku160. Epub 2014 May 26.

引用本文的文献

1
HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic.HIV 暴露前预防:应对艾滋病流行的新型和即将面世的药物。
Drugs. 2023 Dec;83(18):1677-1698. doi: 10.1007/s40265-023-01963-9. Epub 2023 Dec 11.
2
Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.作为成功的抗 HIV-1 阴道杀微生物剂,在阴离子树状聚合物的临床前开发中,基线和时间更新因素。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 May;14(3):e1774. doi: 10.1002/wnan.1774. Epub 2022 Jan 12.
3
Physiologically-based pharmacokinetic model of vaginally administered dapivirine ring and film formulations.阴道给药地匹福林环和膜制剂的基于生理的药代动力学模型。
Br J Clin Pharmacol. 2018 Sep;84(9):1950-1969. doi: 10.1111/bcp.13625. Epub 2018 Jun 19.
4
Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.用于预防女性HIV性传播的阴道杀微生物剂的历史发展:从过去的失败到未来的希望
Drug Des Devel Ther. 2017 Jun 15;11:1767-1787. doi: 10.2147/DDDT.S133170. eCollection 2017.
5
Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.使用液相色谱-串联质谱分析法同时测定猪尾猕猴血浆、阴道分泌物和阴道组织中的依曲韦林、马拉维若和拉替拉韦。
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jul 1;1025:110-8. doi: 10.1016/j.jchromb.2016.04.048. Epub 2016 May 2.
6
Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.用于艾滋病病毒/艾滋病暴露前预防和治疗的药物递送策略与系统
J Control Release. 2015 Dec 10;219:669-680. doi: 10.1016/j.jconrel.2015.08.042. Epub 2015 Aug 24.
7
Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.与HIV性传播相关的组织和细胞中的药物转运体:对药物递送的影响。
J Control Release. 2015 Dec 10;219:681-696. doi: 10.1016/j.jconrel.2015.08.018. Epub 2015 Aug 13.
8
The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.绵羊作为候选杀微生物剂临床前安全性和药代动力学评估的模型。
Antimicrob Agents Chemother. 2015 Jul;59(7):3761-70. doi: 10.1128/AAC.04954-14. Epub 2015 Apr 6.
9
Preclinical evaluation of UC781 microbicide vaginal drug delivery.UC781 杀微生物剂阴道给药剂的临床前评价。
Drug Deliv Transl Res. 2011 Apr;1(2):175-82. doi: 10.1007/s13346-011-0019-1.
10
Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice.达匹韦林纳米颗粒经阴道给药后在小鼠体内的生物分布及药代动力学
Pharm Res. 2014 Jul;31(7):1834-45. doi: 10.1007/s11095-013-1287-x. Epub 2014 Jan 22.

本文引用的文献

1
Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.TMC120(一种有前景的阴道杀菌剂)在HIV阴性和HIV阳性女性志愿者中的剂量范围1期研究。
J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):154-8. doi: 10.1097/QAI.0b013e31802bb35f.
2
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.基于非核苷抑制剂的抗HIV杀微生物剂的曙光。
J Antimicrob Chemother. 2006 Mar;57(3):411-23. doi: 10.1093/jac/dki464. Epub 2006 Jan 23.
3
The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells.非核苷类逆转录酶抑制剂UC-781可抑制1型人类免疫缺陷病毒对人宫颈组织的感染以及迁移细胞的传播。
J Virol. 2005 Sep;79(17):11179-86. doi: 10.1128/JVI.79.17.11179-11186.2005.
4
HIV and sexually transmitted diseases: lethal synergy.艾滋病毒与性传播疾病:致命协同作用。
Top HIV Med. 2004 Oct-Nov;12(4):104-7.
5
Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors.下一代非核苷类逆转录酶抑制剂研发的最新进展
Curr Top Med Chem. 2004;4(10):1045-57. doi: 10.2174/1568026043388295.
6
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.构象和位置适应性在TMC125-R165335(依曲韦林)及相关非核苷类逆转录酶抑制剂基于结构的设计中的作用,这些抑制剂对野生型和耐药HIV-1变体具有高效力和有效性。
J Med Chem. 2004 May 6;47(10):2550-60. doi: 10.1021/jm030558s.
7
In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.非核苷类逆转录酶抑制剂UC-781和TMC120-R147681作为人类免疫缺陷病毒杀微生物剂的体外评价
Antimicrob Agents Chemother. 2004 Jan;48(1):337-9. doi: 10.1128/AAC.48.1.337-339.2004.
8
Disruption of the upper female reproductive tract epithelium by nonoxynol-9.
Contraception. 2003 Oct;68(4):273-9. doi: 10.1016/s0010-7824(03)00178-1.
9
Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation.凝胶制剂中的非核苷类逆转录酶抑制剂TMC120对人源化严重联合免疫缺陷(hu - SCID)小鼠体内HIV - 1阴道传播的抑制作用
AIDS. 2003 Jul 25;17(11):1597-604. doi: 10.1097/00002030-200307250-00003.
10
Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.针对人类免疫缺陷病毒1型(HIV-1)感染的化学屏障:UC781的杀逆转录病毒活性,一种HIV-1逆转录酶的硫代羧酰苯胺类非核苷抑制剂
J Virol. 1997 Apr;71(4):3023-30. doi: 10.1128/JVI.71.4.3023-3030.1997.

连续7天每天一次经阴道给予[14C]达匹韦林凝胶制剂后,恒河猴和兔体内达匹韦林的浓度。

Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days.

作者信息

Nuttall Jeremy P, Thake Daryl C, Lewis Mark G, Ferkany John W, Romano Joseph W, Mitchnick Mark A

机构信息

International Partnership for Microbicides, 8401 Colesville Road, Suite 200, Silver Spring, MD 20910, USA.

出版信息

Antimicrob Agents Chemother. 2008 Mar;52(3):909-14. doi: 10.1128/AAC.00330-07. Epub 2007 Dec 17.

DOI:10.1128/AAC.00330-07
PMID:18086845
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2258487/
Abstract

Dapivirine is a nonnucleoside reverse transcriptase inhibitor being developed as a topical microbicide for the prevention of human immunodeficiency virus infection. The distribution of radioactivity and drug in plasma and in vaginal, cervical, and draining lymph node tissues was investigated after daily application of a vaginal gel formulation of [14C]dapivirine to rhesus macaques. This was preceded by a preliminary study with rabbits. Following the intravaginal administration of [14C]dapivirine ( approximately 0.1 mg/ml [15 microCi/ml]) to rabbits (0.5 ml/day) and macaques (1 ml/day) for 7 days, the dapivirine levels associated with vaginal and cervical tissue samples 1 h after the final dose were high (quantities of microg/g of tissue) and remained detectable at 24 h (mean, >or=2.5 ng/g in rabbits) and 48 h (mean, >80 ng/g in macaques). Radioactivity levels were low in the plasma and very low or unquantifiable in the draining lymph nodes of the macaques. Microautoradiography identified drug-related material (DRM) on the surfaces of the vaginal and cervical tissues of the rabbits and macaques. Although DRM was primarily associated with the outermost layer of shedding cells in rabbits, two animals showed some evidence of small quantities in the mucosal epithelium of the cervix. In macaques, DRM was seen within the keratinized layer of the vaginal epithelium and and was found to extend into the superficial cellular layers, and in at least one animal it appeared to be present in the deepest (germinal) layer of the epithelium and in submucosal tissues. The persistence of biologically significant concentrations of dapivirine in vaginal and cervical tissues for >24 h supports the development of dapivirine as a microbicide for once daily application.

摘要

达匹韦林是一种非核苷类逆转录酶抑制剂,正被开发用作预防人类免疫缺陷病毒感染的局部杀菌剂。在恒河猴每日应用[14C]达匹韦林阴道凝胶制剂后,研究了放射性和药物在血浆以及阴道、宫颈和引流淋巴结组织中的分布情况。在此之前,先对兔子进行了一项初步研究。给兔子(0.5毫升/天)和恒河猴(1毫升/天)阴道内给予[14C]达匹韦林(约0.1毫克/毫升[15微居里/毫升]),持续7天,最终剂量后1小时,与阴道和宫颈组织样本相关的达匹韦林水平很高(微克/克组织量),在24小时(兔子中平均≥2.5纳克/克)和48小时(恒河猴中平均>80纳克/克)仍可检测到。恒河猴血浆中的放射性水平较低,引流淋巴结中的放射性水平非常低或无法定量。显微放射自显影术在兔子和恒河猴的阴道和宫颈组织表面鉴定出了药物相关物质(DRM)。虽然DRM主要与兔子脱落细胞的最外层相关,但有两只动物的宫颈黏膜上皮有少量存在的迹象。在恒河猴中,DRM见于阴道上皮的角质化层内,并延伸至浅表细胞层,在至少一只动物中,它似乎存在于上皮的最深(生发)层和黏膜下组织中。达匹韦林在阴道和宫颈组织中具有生物学意义的浓度持续>24小时,这支持了将达匹韦林开发为每日应用一次的杀菌剂。